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INTRODUCTION
Liver cirrhosis (LC) is a disease with a high rate of prevalence and one of the most common causes of mortality in the Republic of Korea (hereafter "Korea"). In Korea, the main etiologies of LC have been found to be chronic hepatitis B (CHB), alcohol, and chronic hepatitis C (CHC).
In patients with complications such as ascites, variceal bleeding, and encephalopathy, the 5-year survival rates were 32%, 21%, and 40%, respectively, reflecting the poor prognosis of patients with LC. Consequently, a clinical practice guideline appropriate for the medical milieu of Korea is important for both patients and clinicians. (moderate-quality evidence), and C (low-quality evidence).
The strength of recommendation has been classified into 2 categories: strong and weak (Table 1) . Where there was no clear evidence, the recommendations were based on the consensus expert opinion(s) in literature and that of the writing committee.
Diagnosis of LC
LC is a pathologically defined disease, and is clinically 
1-4. Others
The serum markers for liver fibrosis directly or indirectly reflect extracellular matrix metabolism. However, their clinical utility in the diagnosis of LC has not been verified.
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FibroScan has been introduced to measure liver elasticity noninvasively and is an objective diagnostic tool for the diagnosis of LC. However, there is no exact guideline on how to apply it clinically, and there is some variation in its diagnostic accuracy for the diagnosis of LC. Therefore, the practical use of FibroScan is limited. 
2-3. Alcohol
Abstinence is the most important treatment of alcoholic liver disease. 35 Abstinence not only improves fibrosis in hepatic tissue but also reduces portal pressure and inhibits progression to LC. Ultimately, the survival rate of patients in all stages of alcoholic liver disease increases following abstinence, with improvements being observed in up to 66% of patients. 35 Sustained drinking increases the risk of variceal bleeding by portal hypertension and is closely related with mortality.
In severe alcoholic hepatitis, steroid and pentoxifylline therapy have been recommended by several studies. However, the effect of these drugs on fibrosis has not been confirmed; therefore, these medications are not recommended in the treatment of fibrosis as anti-fibrotic therapy.
2-4. Nonalcoholic fatty liver
Treatment of nonalcoholic fatty liver comprises improving insulin resistance, removing risk factors of metabolic syndrome, lifestyle modifications, drug therapy, and operative treatment. [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] Weight loss appears to help in liver steatosis as well as relieves hepatic inflammation and fibrosis. [36] [37] [38] [39] Therefore, the first choice of therapy in nonalcoholic fatty liver disease is weight loss through diet therapy and lifestyle 
2-5. Primary biliary cirrhosis
Ursodeoxycholic acid has been proven to improve primary biliary cirrhosis and is the only drug recognized for its treatment. [53] [54] [55] [56] Ursodeoxycholic acid reduces serum bilirubin levels, which is an important prognostic factor, and delays the progression and deterioration of fibrosis 55, 56 13-15 mg/kg/day is the most effective dose in terms of biological effect and cost-effectiveness. Improvements of liver function tests appear within 6-9 months of therapy in more than 90% of patients. 57 Ursodeoxycholic acid treatment is not known to improve fatigue, itching, bone diseases, or autoimmune reactions associated with primary biliary cirrhosis. 57 
Variceal bleeding
Esophageal variceal bleeding is found in approximately 40% of patients with Child-Pugh A class LC, and in approximately 80% of patients with Child-Pugh C class LC. 58 The risk of variceal bleeding depends on the size of varices, red color sign, and the Child-Pugh classification.
Variceal bleeding due to portal hypertension can be prevented when the value of hepatic venous pressure gradient is lower than 12 mmHg or when it is decreased to lower than 20% of the baseline measurement. 59 
3-1. Diagnosis
It is recommended that all patients undergo endoscopy when they are first diagnosed with LC in order to evaluate the presence of esophageal varix and the risk of bleeding. The first line of therapy includes vasoconstrictors such as terlipressin and somatostatin. 65 Antibiotics are recommended for patients admitted in the hospital. 66 Antibiotic therapy is recommended for 5-7 days to prevent sepsis and rebleeding following endoscopy (Table 2) . 67 Medication and endoscopic therapy are recommended in patients with acute variceal bleeding for the first time. 68 If active bleeding is present, banding of the culprit vessel or that just below the ooze should be performed endoscopically. Nonselective beta-blockers do not lower the incidence of bleeding in patients with small esophageal varices. 71 However, patients with a high risk of bleeding (Child-Pugh class B/C or endoscopic red color sign), are considered for nonselective beta-blocker therapy. 70 The dose of nonselective beta-blockers is adjusted for a reduction in the resting heart rate by 25%, to 55 beats/minute, or until the occurrence of side effects. In Koreans, the mean adjusted dose of propranolol is 160 mg/day. with lesser side effects as compared with EVL. However, additional research is needed before they can be routinely used. 66, 77 Combination therapy with EVL and nonselective beta-blockers for the prevention of first bleeding has shown no differences as compared with monotherapy. 78 
3-4. Prevention of variceal rebleeding

3-4-1. Definition and diagnosis
Variceal rebleeding is defined as bleeding after 5 days of recovery from acute variceal bleeding. 70 It is diagnosed similar to acute variceal bleeding.
3-4-2. Prevention
Nonselective beta-blockers alone or combination therapy with isosorbide mononitrate are known to be effective in the prevention of rebleeding. 79 EVL shows better outcomes than endoscopic injection sclerotherapy in endoscopic therapy for prevention of rebleeding. 80 Rebleeding has been reported in 32% of patients after EVL. Combination therapy of EVL and nonselective beta-blockers has been shown to have better outcomes than EVL alone. 81, 82 TIPS shows a significantly low rebleeding rate as compared with endoscopic therapy. However, it shows a significantly high incidence of hepatic encephalopathy. TIPS is not recommended as a first-line therapy for esophageal variceal bleeding and is recommended only as a rescue therapy when combination therapy fails. 83 Liver transplantation should be considered for patients who meet indications for liver transplantation. 84, 85 If the hepatic venous pressure gradient is reduced to less than 12 mmHg or to more than 20% reduction in baseline levels by medical therapy, the incidence rate of rebleeding is low (10%). 86 In such cases, further endoscopic therapy may not be required.
3-5. Gastric varices
3-5-1. Definition and diagnosis
Gastric varices are enlarged submucosal veins of the stomach that cause critical upper gastrointestinal bleeding.
Gastric varices occur in approximately 20% of patients with portal hypertension, and the bleeding rate in 2 years is known to be 25%. 87 Diagnosis is performed by endoscopy.
Endoscopic ultrasound can also be helpful. 
Ascites
Ascites is the most common complication in LC, occurring in 60% of the patients with compensated LC within 10 years. 113 Ascites appears in 2/3 of the patients who required admission due to LC, 114 and 60% of the patients requiring paracentesis is because of LC. 115 
4-1. Diagnosis
Abdominal ultrasound can diagnose ascites with only 100 mL. 116 Ascites is classified by the amount of fluid as follows:
Grade 1 is diagnosed through imaging study, When peripheral edema is present, the rate of weight loss should be no greater than 1 kg/day. For patients without edema, 0.5 kg/day of weight loss is ideal. 120, 125 If there is no weight loss even with 5 g/day of salt intake, the diet and diuretic dose should be evaluated by examining the amount of urinary sodium excretion per day. 120, 126 Patients with low salt intake should not excrete more than 78 mEq of urinal sodium in 24 hours. In such patients, if urinary sodium excretion is more than 78 mEq, low salt intake is judged not to be followed. When the excretion is less than 78 mEq, the diuretic is considered to be inadequate and the dose needs to be increased. Spot urine Na/K ratio of more than 1 represents 24 hours urine sodium excretion more than 78 mEq. 127 It is important to check the weight loss, vital sign, changes in consciousness level, and the level of plasma sodium, potassium, and creatinine during diuretic administration.
When plasma sodium is more than 126 mEq/L, diuretics can be used without the restriction of water intake. However, when plasma sodium is less than 125 mEq/L, the physician should consider cessation or reduction in the dose of the diuretic and restriction of water intake. If plasma sodium is less than 120 mEq/L, the diuretic and water intake should be stopped and a plasma expander such as albumin should be administered. If plasma sodium is less than 125 mEq/L with kidney dysfunction, the diuretic should be stopped and a plasma expander should be administered. 128 If plasma potassium is less than 3.5 mEq/L, the dose of loop diuretic should be reduced or stopped. If plasma potassium is more than 5.5 mEq/L, the dose of aldosterone antagonist should be reduced. And if plasma potassium is more than 6.0 mEq/L, the aldosterone antagonist should be ceased. 120 
4-2-2. Therapeutic paracentesis (reference to intractable ascites section)
Therapeutic paracentesis is an effective treatment for tension-type ascites, because it relieves the symptoms more quickly than diuretics and shortens hospitalization ( 
4-3-2. Hyponatremia
The diagnostic criterion for hyponatremia is less than 130 mEq/L. 119 A hypervolemic state can be corrected to normal by a negative water balance. Eventually, dilutional hyponatremia can be improved. 136 Restriction of water intake can prevent a decrease in the serum sodium level. 125 Hypertonic sodium injection can worsen ascites and edema. 137 Plasma expanders can be useful in the treatment of hyponatremia. 138 Vaptan, 139 solute-free water. This agent can be used in the treatment of hyponatremia caused by inappropriate antidiuretic hormone secretion, heart failure, or liver cirrhosis. In the United
States and Europe, tolvaptan and conivaptan are approved for the treatment of severe hyponatremia (<125 mEq/L).
4-4. Hepatorenal syndrome
4-4-1. Definition and diagnosis
Renal failure in LC occurs in 2 forms. First, type 1 hepatorenal syndrome is a rapid progressive acute renal dysfunction which occurs due to the strong contraction of the renal vasculature. Type 2 hepatorenal syndrome is a relatively slow process with a rather moderate renal dysfunction. The most important mechanism involved in the occurrence of hepatorenal syndrome is decreased effective blood volume due to the dilation of the splanchnic and peripheral circulation. This situation activates the sympathetic nervous system as well as the renin-angiotensin system and causes functional renal disorder. [140] [141] [142] In 1994, the International Ascites Club announced the diagnostic criteria for hepatorenal syndrome; in 2007, they revised these criteria to providing clearer diagnostic methods and including infectious diseases (Table 5) . 
157-160
After administration of terlipressin, hepatic venous pressure gradient is known to decrease while the renal blood flow increases. 161, 162 Therefore, it can also be used for treatment in patients with secondary renal insufficiency due to variceal bleeding. 147, 163, 164 Although TIPS 157, 165, 166 reduces the serum creatinine levels in most patients with hepatorenal syndrome, the effect is slower than the combined use of terlipressin and albumin.
In a group that used molecular adsorbent recirculating system 167 Hepatorenal syndrome can be prevented by inhibiting the decrease of plasma volume. Diuretics and lactulose should be used carefully to prevent excessive fluid loss. 132, 133, 170, 171 In patients with SBP, the use of albumin and antibiotics reduce the incidence of hepatorenal syndrome. 172, 173 The use of oral norfloxacin has been shown to reduce the occurrence of hepatorenal syndrome and increase 3-month survival rates in patients with low serum protein (<1.5 g/dL) or renal insufficiency (creatinine ≥1.2 mg/dL, or blood urea nitrogen ≥25 mg/dL, or serum Na ≤130 mEq/L). 174 Administration of pentoxifylline improved survival rates as compared to corticosteroids in severe acute alcoholic hepatitis patients (Maddrey's discriminant factor ≥32). (Table 7) . 183 Venous levels of ammonia are not helpful because they are not proportional to the severity of hepatic encephalopathy and some patients with sever hepatic encephalopathy have normal venous ammonia levels. 184 Brain MRI is considered better than brain CT in the diagnosis of brain edema accompanying hepatic failure, but this is not true for hepatic encephalopathy. Brain CT is useful when differentiating between organic causes of neuropsychiatric disorders such as intracranial hemorrhage. 185 
5-3. Treatment
The goal of treatment is to prevent secondary damage caused by decreased consciousness, normalize the patient's state of consciousness, prevent recurrence, and to improve the prognosis and quality of life by eliminating the social and economic restrictions caused by hepatic encephalopathy.
The precipitating factor can be identified in more than 80% of patients with hepatic encephalopathy. 182 The currently known precipitating factors of hepatic encephalopathy and the corresponding tests and treatments are shown in 
5-3-3. Prevention of relapse
Because the recurrence rate of hepatic encephalopathy is 50-70%, 189, 195, 196 therapy for the prevention of recurrence should be considered. Lactulose 189 or rifaximin 196 have been used for the prevention of recurrence.
5-4. Minimal hepatic encephalopathy
5-4-1. Definition and diagnosis
Minimal hepatic encephalopathy is a mild form of hepatic encephalopathy that is defined as a cognitive dysfunction presenting a abnormal psychometric tests without clinical 
